<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01360424</url>
  </required_header>
  <id_info>
    <org_study_id>HUS-LTO-PTH</org_study_id>
    <secondary_id>2010-019297-32</secondary_id>
    <nct_id>NCT01360424</nct_id>
  </id_info>
  <brief_title>Teriparatide Treatment in Patients With Inherited Osteoporosis</brief_title>
  <official_title>Efficacy of Teriparatide Treatment in Patients With New Forms of Inherited Low-Turnover Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyse efficacy of teriparatide treatment in patients with
      new forms of inherited low-turnover osteoporosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in lumbar bone mineral density (BMD)</measure>
    <time_frame>0, 12 and 24 months</time_frame>
    <description>The primary outcome measure is the change in lumbar BMD measured with dual-energy X-ray absorptiometry (DXA) during the 24 months treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in whole body bone mineral density (DXA)</measure>
    <time_frame>0,12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hip bone mineral density (DXA)</measure>
    <time_frame>0,12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in histomorphometry of bone biopsy samples</measure>
    <time_frame>0 and 24 months</time_frame>
    <description>includes e.g following parameters: Bone volume (BV/TV, %); Osteoid volume (OV/BV, %); Trabecular thickness (Tb.Th, um); Osteoid surface (OS/BS, %); Osteoblast surface (Ob.S/BS, %); Eroded surface (ES/BS, %); Osteoclast surface (Oc.S/BS, %); Mineral apposition rate (MAR, um/day); Mineralizing surface (MS/BS, %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in bone microarchitecture assessed by micro computed tomography of bone biopsy samples</measure>
    <time_frame>0 and 24 months</time_frame>
    <description>includes e.g following parameters: bone volume (BV, mm3); relative bone volume (BV/TV, %); connectivity density, (Conn.D., 1/mm3); trabecular number (DT-Tb.N, 1/mm); trabecular thickness (DT-Tb.Th, mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in peripheral quantitative computed tomography (pQCT) measured cortical and trabecular volumetric bone mineral density of tibia and radius</measure>
    <time_frame>0,12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of vertebral fractures (spine X-ray)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum procollagen type I N-terminal propeptide (PINP)</measure>
    <time_frame>0,3,6,12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum type I collagen C-telopeptides (CTX)</measure>
    <time_frame>0,3,6,12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in serum osteocalcin</measure>
    <time_frame>0,3,6,12 and 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>teriparatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>Daily administration of teriparatide 20 ug s.c. for 24 months</description>
    <arm_group_label>teriparatide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  inherited low-turnover osteoporosis

          -  lumbar spine or hip BMD T-score ≤ -2.5

          -  a written informed consent.

        Exclusion Criteria:

          -  age less than 18 years

          -  generally accepted contraindications for the treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matti Välimäki, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Orthopaedics and Traumatology and Division of Endocrinology, Department of Medicine and Pediatric Endocrinology, Hospital for Children and Adolescents, Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2011</study_first_submitted>
  <study_first_submitted_qc>May 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2011</study_first_posted>
  <last_update_submitted>September 27, 2015</last_update_submitted>
  <last_update_submitted_qc>September 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Ville-Valtteri Välimäki</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>teriparatide</keyword>
  <keyword>bone turnover</keyword>
  <keyword>New forms of inherited low-turnover osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

